Lineage Cell Therapeutics, Inc. (LCTX)

1,0600 +0,0100 (+0,95%) Börsenschluss: 04:00PM EDT

Lineage Cell Therapeutics, Inc.

2173 Salk Avenue
Suite 200
Carlsbad, CA 92008
United States
442 287 8990
https://www.lineagecell.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 68

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Brian M. Culley M.A., M.B.A.	CEO, President & Director	986,7k	N/A	1971
Ms. Jill Ann Howe	CFO & Principal Financial and Accounting Officer	587,4k	N/A	1977
Mr. George A. Samuel III, J.D.	General Counsel & Company Secretary	554,51k	N/A	1981
Ioana C. Hone	Director of Investor Relations	N/A	N/A	N/A
Dr. Charlotte Hubbert Ph.D.	Vice President of Corporate Development	N/A	N/A	N/A
Ms. Brandi L. Roberts CPA, M.B.A.	Consultant	407,45k	N/A	1974
Mr. William Annett MBA	President & CEO of OncoCyte Corporation	53,2k	N/A	1954
Dr. Rami Skaliter Ph.D.	Chief Executive Officer of Cell Cure Neurosciences	N/A	N/A	1958
Ms. Alexandra Hernandez	Senior Director of Finance & Controller	N/A	N/A	N/A
Dr. Harold D. Waitz	Vice President of Regulatory Affairs & Quality Control	90k	N/A	1942

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Corporate Governance

Lineage Cell Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 4. Die grundlegenden Scores sind Audit: 3, Vorstand: 7, Shareholderrechte: 2, Kompensation: 6.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.